SCHEMBL31268984

SCHEMBL31268984

Cc1ccnc(Cn2c(-c3ccc(S(N)(=O)=O)cc3Cl)nc3c(OC4(C)CC4)ncnc32)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 3/20 0.33
▸ PARG Q86W56 1/20 0.33
▸ SCN8A Q9UQD0 2/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ SCN1A P35498 1/20 0.31
▸ CA1 P00915 5/20 0.31
▸ CA2 P00918 5/20 0.31
▸ CA9 Q16790 5/20 0.31
▸ CA4 P22748 2/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ CHRNA7 P36544 1/20 0.31
▸ CA12 O43570 4/20 0.30
▸ CA6 P23280 1/20 0.30
▸ CA5A P35218 1/20 0.30
▸ CA7 P43166 1/20 0.30
▸ CA14 Q9ULX7 1/20 0.30
▸ CA5B Q9Y2D0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269244 0.93 KMT2A (0.34) PIK3CDPARGSCN8AKCNH2SCN5A
SCHEMBL31269032 0.91 PARG (0.37) PIK3CDPARGSCN8AKCNH2SCN5A
SCHEMBL31269215 0.88 KCNH2 (0.34) PIK3CDKCNH2SCN5ASCN9A
SCHEMBL30983829 0.86 KCNH2 (0.34) PIK3CDKCNH2SCN5ASCN9A
SCHEMBL30983779 0.86 KCNH2 (0.36) PIK3CDKCNH2SCN5ASCN9APTGS1
SCHEMBL31269077 0.86 HAVCR2 (0.33) PIK3CDSCN8AKCNH2SCN5ASCN9A
SCHEMBL31269136 0.86 PIK3CD (0.36) PIK3CDKCNH2SCN5ASCN9A
SCHEMBL31269475 0.85 PIK3CD (0.37) PIK3CDKCNH2SCN5ASCN9A
SCHEMBL30983484 0.84 PIK3CD (0.36) PIK3CDKCNH2SCN5ASCN9A
SCHEMBL31268950 0.84 KCNH2 (0.32) PIK3CDKCNH2SCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback